Disc Medicine, Inc. - Common Stock (NQ:IRON)

65.48 -2.43 (-3.58%)

Streaming Delayed Price Updated: 11:20 AM EST, Feb 27, 2026 Add to My Watchlist

Price and Volume

Volume	28,777
Open	67.49
Bid (Size)	65.44 (100)
Ask (Size)	65.94 (100)
Prev. Close	67.91
Today's Range	64.92 - 67.86
52wk Range	30.82 - 99.50
Shares Outstanding	22,877,552
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Disc Medicine Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

February 26, 2026

From Disc Medicine Inc

Via GlobeNewswire

Disc Medicine Stock Is Swinging, but This Fund's New $52 Million Bet Shows Conviction ↗

February 25, 2026

Disc Medicine develops therapies for rare blood disorders, leveraging clinical-stage biotech expertise in red blood cell biology.

Via The Motley Fool

Performance

YTD	-17.2%	-17.2%
1 Month	-20.3%	-20.3%
3 Month	-29.9%	-29.9%
6 Month	+9.8%	+9.8%
1 Year	+20.2%	+20.2%

More News

Apogee Therapeutics Stock Up 100% as Fund Lifts Stake to $28 Million ↗

February 25, 2026

Via The Motley Fool

Disc Medicine, Sanofi, Eli Lilly Shares Slip On Reports Of FDA Increasing Review Time For Drugs Granted Priority Review Vouchers ↗

January 15, 2026

Via Stocktwits

This Fund Bet $20 Million on RAPT Therapeutics as Stock Surges 500% This Past Year and Buyout Offer Emerges ↗

February 25, 2026

Via The Motley Fool

Disc Medicine Lands New $20 Million Investment as FDA Sets Up Potential Q4 Catalyst ↗

February 25, 2026

Via The Motley Fool

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc Medicine, Inc.- IRON

February 24, 2026

From Pomerantz LLP

Via GlobeNewswire

Disc Medicine to Participate in Upcoming Investor Conferences

February 24, 2026

From Disc Medicine Inc

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc Medicine, Inc.- IRON

February 17, 2026

From Pomerantz LLP

Via GlobeNewswire

Disc Medicine Stock Slumps After FDA Declines Approval For Inherited Disorder Drug Over Efficacy Concerns ↗

February 13, 2026

Via Stocktwits

Disc Medicine Receives Complete Response Letter from FDA for Bitopertin for the Treatment of EPP

February 13, 2026

From Disc Medicine Inc

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc Medicine, Inc.- IRON

February 03, 2026

From Pomerantz LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Disc Medicine, Inc. – IRON

January 27, 2026

From Pomerantz LLP

Via GlobeNewswire

Disc Medicine Appoints Lisa Amaya Price, MBA as Chief Human Resources Officer

January 12, 2026

From Disc Medicine Inc

Via GlobeNewswire

Disc Medicine Highlights Recent Achievements and Key Business Objectives and Milestones for 2026

January 12, 2026

From Disc Medicine Inc

Via GlobeNewswire

What Investors Should Know About a $511K Disc Medicine Insider Sale and a 26% Stock Run ↗

January 11, 2026

Via The Motley Fool

Disc Medicine to Present at the 44th Annual J.P. Morgan Healthcare Conference

January 07, 2026

From Disc Medicine Inc

Via GlobeNewswire

Disc Medicine Stock Slides After FDA Fast-Track Approval Doubts Surface — Wall Street Calls It An ‘Overreaction’ ↗

December 19, 2025

Via Stocktwits

Disc Medicine Presents Positive Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH) Annual Meeting

December 06, 2025

From Disc Medicine Inc

Via GlobeNewswire

Portfolio Adjustment: Institutional Heavyweight Exits Biotech Stock ↗

November 19, 2025

Via The Motley Fool

Disc Medicine Inc (NASDAQ:IRON) Reports Wider-Than-Expected Q3 2025 Loss Amid Pipeline Advancements ↗

November 06, 2025

Via Chartmill

Disc Medicine Reports Third Quarter 2025 Financial Results and Provides Business Update

November 06, 2025

From Disc Medicine Inc

Via GlobeNewswire

Disc Medicine Announces Presentation of Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH) Annual Meeting

November 03, 2025

From Disc Medicine Inc

Via GlobeNewswire

Disc Medicine to Participate in Upcoming Investor Conferences

October 31, 2025

From Disc Medicine Inc

Via GlobeNewswire

Disc Medicine Announces Pricing of $250 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants

October 21, 2025

From Disc Medicine Inc

Via GlobeNewswire

Frequently Asked Questions

Is Disc Medicine, Inc. - Common Stock publicly traded?

Yes, Disc Medicine, Inc. - Common Stock is publicly traded.

What exchange does Disc Medicine, Inc. - Common Stock trade on?

Disc Medicine, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Disc Medicine, Inc. - Common Stock?

The ticker symbol for Disc Medicine, Inc. - Common Stock is IRON on the Nasdaq Stock Market

What is the current price of Disc Medicine, Inc. - Common Stock?

The current price of Disc Medicine, Inc. - Common Stock is 65.48

When was Disc Medicine, Inc. - Common Stock last traded?

The last trade of Disc Medicine, Inc. - Common Stock was at 02/27/26 11:20 AM ET

What is the market capitalization of Disc Medicine, Inc. - Common Stock?

The market capitalization of Disc Medicine, Inc. - Common Stock is 1.50B

How many shares of Disc Medicine, Inc. - Common Stock are outstanding?

Disc Medicine, Inc. - Common Stock has 1B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.